STOCK TITAN
  1. Home
  2. Sec-filings
  3. HURA
  4. [8-K] TuHURA Biosciences, Inc./NV Reports Material Event

TuHURA Biosciences borrows $1.5M from credit line

TuHURA Biosciences drew an additional $1.5 million under its $50 million revolving credit facility for general corporate purposes.

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

TuHURA Biosciences, Inc. (HURA) reports a new borrowing under its existing revolving credit facility with Parkview Holdings One LLC. The facility, previously disclosed, has a maximum availability of $50 million and matures on April 21, 2031. On September 2, 2026, the company drew an additional $1,500,000 and states it expects to use the funds for general corporate purposes.

The company highlights forward-looking risks related to its ability to continue drawing funds under the Loan Agreement, the possibility that available funds may not be sufficient for its operations and development programs, and notes potential conflicts of interest because the lender is an affiliate of its largest stockholder.

Positive

  • None.

Negative

  • None.

Filing Explained

The latest reported quarter ended June 30, 2026 with $995,977 in cash; its $8,633,599 operating cash outflow makes that balance equal 10.5 days at that historical rate.

Sources and calculations
  • Available liquidity against the last reported quarterly operating outflow, in days at that rate $995,977 / ($8,633,599 / 91) = 10.5 days
Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement Financial
The company incurred a new significant debt or off-balance-sheet obligation.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Revolving credit facility maximum availability $50,000,000 Maximum amount of loan availability under the Loan Agreement
New borrowing amount $1,500,000 Additional draw under the revolving credit facility on September 2, 2026
Loan Agreement maturity date April 21, 2031 Stated maturity of the revolving credit facility
Form type 8-K Current report disclosing creation of a direct financial obligation
Exhibit 104 Cover Page Interactive Data File Inline XBRL data file referenced in the exhibits section
revolving credit facility financial
"provides for a revolving credit facility that matures on April 21, 2031"
A revolving credit facility is a type of loan that a business can borrow from whenever it needs money, up to a set limit. It’s like having a credit card for companies—allowing them to borrow, pay back, and borrow again as needed, providing flexibility for managing cash flow or funding short-term expenses.
off-balance sheet arrangement financial
"Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement"
An off-balance sheet arrangement is a financial commitment or asset that a company keeps out of its main financial statements so it does not show up as a direct asset or liability. Think of it like renting equipment or using a separate storage locker instead of putting the item in your home: the economic effects exist, but they aren’t listed on the company’s primary balance sheet. Investors care because these arrangements can hide risks, obligations or sources of cash flow that affect a company’s true financial strength and future performance.
forward-looking statements regulatory
"contains certain “forward-looking statements” within the meaning of, and subject to the safe harbor"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
safe harbor regulatory
"subject to the safe harbor created by Section 27A of the Securities Act of 1933"
Safe harbor is a rule that protects companies or individuals from legal trouble if they follow certain guidelines or procedures. It’s like having a safety net that allows them to act without fear of punishment, as long as they stick to the rules. This helps encourage honest behavior and clear standards in financial and legal activities.

FAQ

What new debt did TuHURA Biosciences (HURA) incur in this 8-K?
TuHURA Biosciences reports borrowing an additional $1,500,000 on September 2, 2026 under its existing revolving credit facility with Parkview Holdings One LLC, and states it expects to use these funds for general corporate purposes.

What is the total size and maturity of TuHURA Biosciences' revolving credit facility?
The Loan Agreement provides a revolving credit facility with a maximum loan availability of $50 million that matures on April 21, 2031, giving TuHURA Biosciences access to this financing over a multi-year term.

Who is the lender under TuHURA Biosciences' Loan Agreement mentioned in the 8-K?
The lender under the Loan Agreement is Parkview Holdings One LLC. TuHURA Biosciences notes that this entity is an affiliate of the company’s largest stockholder, which it identifies as a potential source of conflicts of interest.

How does TuHURA Biosciences (HURA) plan to use the new $1.5 million draw?
TuHURA Biosciences states that it expects to use the additional $1,500,000 drawn under the revolving credit facility for general corporate purposes, without further breakdown in this report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0001498382falseTuHURA Biosciences, Inc./NV00014983822026-09-022026-09-02

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 2, 2026

TUHURA BIOSCIENCES, INC.

(Exact name of Registrant as Specified in Its Charter)

 

Nevada

001-37823

99-0360497

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

10500 University Center Dr., Suite 110

Tampa, Florida 33612

(Address of Principal Executive Offices, including zip code)

Registrant’s Telephone Number, Including Area Code: (813) 875-6600

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

Trading
Symbol(s)


Name of each exchange on which registered

Common Stock, $0.001 par value per share

 

HURA

The Nasdaq Capital Market

 

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

 

As previously disclosed, on April 21, 2026, TuHURA Biosciences, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Parkview Holdings One LLC, as lender. The Loan Agreement provides for a revolving credit facility that matures on April 21, 2031, with a maximum amount of loan availability of $50 million. On September 2, 2026, the Company received and borrowed an additional draw under the revolving credit facility in the amount $1,500,000 and expects to use the funds for general corporate purposes.

 

The description of the Loan Agreement contained herein does not purport to be complete and is qualified in its entirety by reference to the complete text of the Loan Agreement, a copy of which was filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on April 22, 2026.

 

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit No

 

104 Cover Page Interactive Data File (embedded within the inline XBRL document)

 

 

 

Forward-Looking Statements

 

This Current Report on Form 8-K contains certain “forward-looking statements” within the meaning of, and subject to the safe harbor created by Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based only on the Company’s current beliefs, expectations and assumptions regarding the future of the Company’s business, future plans and strategies, projections, anticipated events and other future conditions. In some cases, you can identify these statements by forward-looking words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “could,” “should,” “would,” “project,” “plan,” “expect,” “goal,” “seek,” “future,” “likely,” or the negative or plural of these words or similar expressions. Examples of such forward-looking statements include, but are not limited to, express or implied statements regarding the Company’s expectations, hopes, beliefs, or intentions regarding: the Company’s ability to draw down sufficient funds against the Loan Agreement and the Company’s needs and expectations regarding existing and future capital resources and expenses and the Company’s need for additional capital. You are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in these forward-looking statements. Factors that could cause actual results to differ materially from these forward-looking statements include, among others: the risk that the Company may be unable to satisfy conditions to drawdown or maintain compliance with the terms of the Loan Agreement; the risk that funds available under the Loan Agreement may be insufficient to fund the Company’s operations and development programs to the extent anticipated; potential conflicts of interest arising from the Loan Agreement with an affiliate of the Company’s largest stockholder; and the other risks described from time to time in detail in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as filed on March 31, 2026, and the Company’s other reports and filings with the SEC from time to time, which are available on the Company’s website and at www.sec.gov.

 

The forward-looking statements and other information contained in this Current Report on Form 8-K are made as of the date hereof, and the Company does not undertake any obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

 

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TUHURA BIOSCIENCES, INC.

Date:

September 4, 2026

By:

/s/ Dan Dearborn

Name: Dan Dearborn
Title: Chief Financial Officer

 

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document

Other Documents

Keep reading

More on HURA

Trending in the feed

Open the live feed